Prognostic and Predictive Values of Transcriptomic Signatures in Metastatic Pancreatic Cancer: A Biomarker Analysis of Three French Multicenter Prospective Randomized Controlled Phase 2 Trials (Prodige35, Prodige37 and AFUGEM)
{{output}}
To evaluate the clinical applicability of previously established transcriptomic signatures (molecular subtypes, components and GemPred status) in metastatic pancreatic cancer, we conducted a retrospective pooled analysis of 178 patients from three phase 2 tria... ...
